Bray G A, Tartaglia L A
Pennington Biomedical Research Center, Baton Rouge, Louisiana 70808, USA.
Nature. 2000 Apr 6;404(6778):672-7. doi: 10.1038/35007544.
When prevention fails, medicinal treatment of obesity may become a necessity. Any strategic medicinal development must recognize that obesity is a chronic, stigmatized and costly disease that is increasing in prevalence. Because obesity can rarely be cured, treatment strategies are effective only as long as they are used, and combined therapy may be more effective than monotherapy. For a drug to have significant impact on body weight it must ultimately reduce energy intake, increase energy expenditure, or both. Currently approved drugs for long-term treatment of obesity include sibutramine, which inhibits food intake, and orlistat, which blocks fat digestion.
当预防措施失败时，药物治疗肥胖可能成为必要手段。任何战略性药物研发都必须认识到，肥胖是一种慢性、受污名化且代价高昂的疾病，其患病率正在上升。由于肥胖很少能被治愈，治疗策略只有在使用期间才有效，联合治疗可能比单一疗法更有效。一种药物要对体重产生显著影响，最终必须减少能量摄入、增加能量消耗，或者两者兼而有之。目前被批准用于长期治疗肥胖的药物包括抑制食物摄入的西布曲明和阻止脂肪消化的奥利司他。
